Gary Lowell Engel
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gary Lowell Engel.
International Journal of Pharmaceutics | 2000
Gary Lowell Engel; Nagy A. Farid; Margaret M. Faul; Lori Ann Richardson; Leonard L. Winneroski
LY333531 is a potent protein kinase C(beta) (PKC(beta)) inhibitor currently under development for the treatment of diabetic complications. Seven salts of LY333531 (hydrochloride, sulfate, mesylate, succinate, tartrate, acetate and phosphate) were evaluated during the early phase of development. Physical property screening techniques including microscopy, DSC, TGA, XRPD, hygroscopicity and solubility were utilized to narrow the selection to two salts: the mesylate and hydrochloride. Identification of the optimal salt form was based upon solubility, bioavailability, physical stability and purity. During the evaluation process three hydrated forms (anhydrate, monohydrate, and tetrahydrate) of the hydrochloride salt were identified. The mesylate salt was found to give only one, a monohydrate. Processing parameters (e.g. filtration rate, crystal form stability) demonstrated that the anhydrate was the preferred form of the hydrochloride salt. Bioavailability studies in dogs indicated that the C(max) and area under the plasma concentration vs. time curve (AUC) for LY333531 and its active metabolite, LY338522, following administration of the mesylate salt were approximately 2.6 times those obtained after the LY333531 HCl dose. This difference was presumed to be due primarily to the fact that the mesylate was five times more soluble than the hydrochloride salt in water. These factors led to selection and development of LY333531 mesylate monohydrate as the active pharmaceutical ingredient for clinical evaluation.
Antimicrobial Agents and Chemotherapy | 1976
Ralph R. Pfeiffer; Gary Lowell Engel; Dennis Coleman
Two methods of preparing sensitivity disks were compared for their effect on disk stability at 25 and 37 C. One method consisted of applying a solution of the antibiotic to blank disks by the conventional procedure; the second method consisted of applying the antibiotic to the disks as a suspension of crystals. Of the four β-lactam antibiotics that were studied, disks made with suspended crystals were substantially more stable than corresponding disks made by the conventional method. The increased stability is related to the greater chemical stability of the antibiotics in the crystalline versus the amorphous state. Images
Archive | 1996
Gary Lowell Engel; Nagy A. Farid; Margaret M. Faul; Michael R. Jirousek; Lori Ann Richardson; Leonard L. Winneroski
Journal of Pharmacy and Pharmacology | 1981
Joseph M. Indelicato; Douglas E. Dorman; Gary Lowell Engel
Journal of Pharmaceutical Sciences | 1985
Joseph M. Indelicato; Gary Lowell Engel; John L. Occolowitz
Archive | 1983
Gary Lowell Engel; Joseph M. Indelicato; Harry A. Rose
Journal of Pharmaceutical Sciences | 1992
Gregory F. Needham; Ralph R. Pfeiffer; Gary Lowell Engel; Bonnie S. Rutherford; D.J. Allen
Journal of Pharmaceutical Sciences | 1980
Joseph M. Indelicato; Barbara A. Stewart; Gary Lowell Engel
Archive | 1974
Ralph R. Pfeiffer; Gary Lowell Engel
Archive | 1989
Gary Lowell Engel; Ralph Roberts Pfeiffer